Hepatocellular Carcinoma


Treatment of Hepatocellular Carcinoma


Hepatocellular carcinoma (HCC, also called malignant hematoma), is a common and rapidly progressing malignancy of liver and may be caused either by a viral infection (hepatitis B or C) or cirrhosis (alcoholism). Other contributing factors for HCC can be toxins like aflatoxin, Hemochromatosis, Wilson's disease (although debatable), Type 2 Diabetes (probably aided by obesity).

Treatments of Hepatocellular Carcinoma may include one or more combination of liver transplantation, use of a receptor tyrosine kinase inhibitor, surgery, percutaneous ethanol injection (PEI), trans catheter arterial chemoembolization (TACE), radiofrequency ablation (RFA), chemotherapy, Cryosurgery. However the drawback of these treatments may be less survival rate of the patient, treatment is not suitable because of poor liver function or poor health of patient and the most important chances of recurrence of cancer. Studies have been conducted and proved that immunotherapeutic treatment based on Dendritic cell (DC) in the treatment of HCC following surgery can not only treat HCC but also can prevent its recurrence. Many clinical trials indicate that autologous dendritic cell based therapy is a safe treatment for HCC. Dendritic Cells, prepared from peripheral blood monocytes pulsed with autologous tumour lysates has been used to treat HCC. Pulsed Dendritic Cellinfusion followed by boosters can provide better clinical survival for advanced HCC patients